AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00178256 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Thoracic XRT will be given in late afternoon, after 4:00 PM, if possible
Study NCT02900781 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Steprite™
Description: Steprite™ Device shoe insert monitoring device
Study NCT02900781 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: No Device. Standard of care physical therapy
Study NCT02472314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.3% Liposomal Bupivacaine
Description: local tissue infiltration of Liposomal Bupivacaine during surgery
Study NCT02472314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.125% Bupivacaine
Description: Continues nerve block with Bupivacaine during surgery and postoperatively
Study NCT03667716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COM701
Description: COM701 monotherapy.
Study NCT03667716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COM701 with Opdivo (Nivolumab).
Description: COM701 in combination with Opdivo (Nivolumab).
Study NCT00440674 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoStar Paclitaxel-eluting coronary stent system
Study NCT00524238 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: L-thyroxine
Description: The hypothyroid patients receive usual treatment with L-thyroxine in our out patient clinic. The doctors there subscribe the medication, this study has no protocol regarding this, we observe the patients again after having been biochemically euthyroid for at least two months.
Study NCT01510613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide and Dexamethasone
Description: Pomalidomide: 2-4mg/day, every day in cycles of 28 days until progression or unacceptable toxicity Dexamethasone: 20-40mg/week, on days 1, 8, 15, 22 in cycles of 28 days until progression or unacceptable toxicity
Study NCT03507829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human insulin isophane, Humulin N (Eli Lilly)
Description: Human insulin isophane, Humulin N (Eli Lilly)
Study NCT03507829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Sliding scale short acting insulin for hyperglycemia; Sulphonylurea for NODAT
Study NCT03507829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin lispro, Humalog (Eli Lilly) in insulin pump
Description: Insulin lispro, Humalog (Eli Lilly) in insulin pump
Study NCT03089372 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ARIES-ED device
Description: The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites).
Study NCT03443596 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Early intensive BP control
Description: Participants in the early intensive BP control arm are treated with BP lowering medications, with an aim to bring the systolic BP to 140-160mmHg and maintain this level for 72 hours post-ictus
Study NCT01477749 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Description: Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
Study NCT04027335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: leva
Description: Vaginal device used for pelvic floor muscle exercises
Study NCT03076658 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: EOS imaging
Description: The EOS imaging system will be utilized to obtain full-body radiographs in frontal and sagittal projections obtained in the upright standing position. Measurements will include a coronal plumb-line, sagittal vertebral axis (SVA), external auditory meatus plumb-line, cervical lordosis, thoracic kyphosis, lumbar lordosis, hip flexion/extension, knee flexion/extension, ankle flexion/extension, T1 tilt, T1 spino-pelvic instance, acetabular index, pelvic tilt (PT), pelvic incidence (PI), and sacral slope (SS).
Study NCT03560141 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LID011121 contact lens
Description: Investigational silicone hydrogel contact lens
Study NCT03560141 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A contact lens
Description: Commercially available silicone hydrogel contact lens
Study NCT03670147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PF-SCS programming
Description: In a blinded fashion, the study physician will ask subjects to switch their PF-SCS to the LAP.
Study NCT03897166 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trimodality
Description: Positron Emission Tomography coupled with Computed tomography and immediately followed by Magnetic Resonance Imaging
Study NCT03164733 — intervention group
Intervention type: OTHER
Intervention: incubation
Description: standardized wear particles are co-incubated with isolated patient cells (monocytes)
Study NCT00479037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Full Length Parathyroid Hormone, PTH(1-84)
Description: Once daily subcutaneous injection in the abdomen by self administration
Study NCT00479037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Strontium Ranelate
Description: The daily dose of 2 g (one sachet) strontium ranelate was to be mixed in a glass of water and taken immediately after mixing at bedtime at least 2 hours before or after intake of calcium, any food or drinks, other than water
Study NCT03406234 — intervention group
Intervention type: OTHER
Intervention: No intervention.
Description: Cross-sectional observation without interventions.
Study NCT03562169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib, thalidomide, & dexamethasone (ITD) re-induction
Description: 4 - 6 ITD 28-day cycles as follows:~* Ixazomib 4mg capsule on days 1, 8 and 15~* Thalidomide 100mg capsule on days 1-28~* Dexamethasone 40mg tablets on days 1, 8, 15 and 22
Study NCT03562169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixazomib, thalidomide, & dexamethasone (ITD) re-induction
Description: 4 - 6 ITD 28-day cycles as follows:~* Ixazomib 4mg capsule on days 1, 8 and 15~* Thalidomide 100mg capsule on days 1-28~* Dexamethasone 40mg tablets on days 1, 8, 15 and 22
Study NCT03562169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional autologous stem cell transplant (ASCT-con)
Description: Melphalan 200mg/m2 IV infusion on Day -1, followed by ASCT on Day 0.
Study NCT03562169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Augmented autologous stem cell transplant (ASCT-aug)
Description: Melphalan 100mg/m2 IV infusion on Day -3 and Day -2 plus ixazomib 4mg capsules on Day -4 and Day -1. ASCT will then be given on Day 0.
Study NCT03562169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITD consolidation and ixazomib maintenance vs. No further therapy
Description: Participants will be randomised to either 'no further therapy' or 'ITD consolidation and ixazomib maintenance'. Participants randomised to 'no further treatment' will not receive any further treatment but will be followed up at 8 weeks post randomisation 2 and at 3-monthly clinic visits until disease progression.~Participants randomised to ITD consolidation and ixazomib maintenance will receive:~Two 28-day cycles of ITD consolidation (same doses as in ITD re-induction). This will be followed by ixazomib maintenance as follows: Ixazomib 4mg capsule on days 1, 8 and 15 of each 28-day cycle until disease progression.
Study NCT03562169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ITD consolidation and ixazomib maintenance vs. No further therapy
Description: Participants will be randomised to either 'no further therapy' or 'ITD consolidation and ixazomib maintenance'. Participants randomised to 'no further treatment' will not receive any further treatment but will be followed up at 8 weeks post randomisation 2 and at 3-monthly clinic visits until disease progression.~Participants randomised to ITD consolidation and ixazomib maintenance will receive:~Two 28-day cycles of ITD consolidation (same doses as in ITD re-induction). This will be followed by ixazomib maintenance as follows: Ixazomib 4mg capsule on days 1, 8 and 15 of each 28-day cycle until disease progression.
Study NCT00884286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aplidin®
Description: Aplidin® will be administered at a starting dose of 3.2 mg/m2, as a 1-hour intravenous infusion, on days 1, 8 and 15, every 28 days cycle.
Study NCT01406561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS103HP-S
Description: Proprietary concentration and formulation of OMS103HP in solution (OMS103HP-S) for injection into each 3 liter vehicle irrigation solution bag for use during meniscectomy surgery
Study NCT01406561 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: 3 Liter bags of vehicle irrigation solution for use during meniscectomy surgery
Study NCT01779921 — intervention group
Intervention type: DRUG
Intervention: activated recombinant human factor VII
Description: Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
Study NCT01779921 — intervention group
Intervention type: DRUG
Intervention: Fresh frozen plasma (Source unspecified)
Description: Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
Study NCT01779921 — intervention group
Intervention type: DRUG
Intervention: Plasma-derived FVII (LFB)
Description: Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
Study NCT01779921 — intervention group
Intervention type: DRUG
Intervention: Prothrombin Complex conc. (PCC)
Description: Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
Study NCT01779921 — intervention group
Intervention type: DRUG
Intervention: Plasma-derived FVII conc. (pdFVII Baxter)
Description: Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
Study NCT01779921 — intervention group
Intervention type: DRUG
Intervention: Plasma-derived FVII conc. (pdFVII PFL)
Description: Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
Study NCT01010893 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with Fluval P and Fluval AB influenza vaccines
Description: Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 6 μg HA/ in both age groups, single dose) AND with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 3x15 μg HA/ in both age groups, single dose).
Study NCT01010893 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with Fluval P monovalent influenza vaccine
Description: Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant
Study NCT03531463 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative treatment with Reversed Total Shoulder Prosthesis
Description: The standardized approach is the delto-pectoral to minimize any damage of the deltoid muscle. A cemented monoblock humeral stem will be implanted. Braided polyester suture-cerclages engaging the insertion of the subscapular and infraspinatus tendons enforced by a bonegraft or a horseshoe-graft from the humeral head will be used
Study NCT01336335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP
Study NCT01203241 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein encircling
Description: Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum
Study NCT01203241 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein encircling plus roof ablation
Description: Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum plus creation of a radiofrequency line joining contralateral superior pulmonary veins throughout the left atrial roof.
Study NCT01817543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoloGel
Description: Autologel is a platelet-rich plasma gel used in the treatment of non-healing wounds
Study NCT01785641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftazidime+ciprofloxacin
Description: 2 synergistic antibiotics: ceftazidime IP + ciprofloxacin po for gram negative bacterial peritonitis
Study NCT01785641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftazidime monotherapy
Description: ceftazidime IP for gram negative bacterial peritonitis
Study NCT01785641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefazolin+gentamicin
Description: cefazolin IP + gentamicin IP for gram positive bacterial peritonitis
Study NCT01785641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefazolin monotherapy
Description: cefazolin IP for gram positive bacterial peritonitis
Study NCT00636584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium nitroprusside
Description: sodium nitroprusside infusion at 1 microgram/kg/min dose during rewarming period of cardiac operations
Study NCT00636584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03100695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concentrated autologous PRP-BMA
Description: Injection of autologous, concentrated platelet-rich plasma and bone marrow aspirate at the site of fixation.
Study NCT03189225 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Capillary And Venous Accuracy
Description: Capillary And Venous Accuracy: LifeScan Products vs Hospital Reference instrument and LifeScan reference instrument (YSI 2300)
Study NCT03267329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duowell®
Description: telmisartan 80mg/rosuvastatin 10mg for ASCVD risk=5%\~7.5% or telmisartan 80mg/rosuvastatin 20mg for ASCVD risk≥7.5%
Study NCT03267329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: telmisartan 80mg
Study NCT03839563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Each session will last 60 min, consisting of 10 min of warm-up, 45 min of exercise, and a 5-min cool-down.
Study NCT02912195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Description: Intravenous lidocaine drip over 10 minutes followed by intravenous lidocaine drip over 50 minutes
Study NCT02912195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous morphine
Description: Emergency department provider chooses appropriate dose of intravenous morphine
Study NCT02095600 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgical thalamotomy
Study NCT01515956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 110
Description: Patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg/wk over a period of approximately 4 hours every week for up to 208 weeks.
Study NCT00178620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reteplase 10 Units (U) plus a second dose of reteplase 10 U
Description: Thrombolytic-clot busting drug Retavase IV Bolus, 10 U followed by a second 10U dose
Study NCT00178620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reteplase 10 U
Description: Thrombolytic-clot busting drug Retavase IV Bolus in one 10U dose
Study NCT00178620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urgent Percutaneous Coronary Intervention (PCI)
Study NCT01260181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg tablet will be given orally daily.
Study NCT01312792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amoxycilline, Cephradine followed by follow up on day 3
Description: Modified IMCI Guideline for treating severe phnemonia will be implemented in the arm 1. The Modified IMCI guideline denotes that all severe pneumonia cases with only chest indrawing and no other danger signs will be treated at the first level health facilities with first line oral antibiotics followed by follow-up on 3rd day. On 3rd day the patient will be reassessed and if the condition improves the first line antiobiotic will be continued and if deteriorates or remain unchange second line antibiotic will be used. The patient will be further asked to come on day 3 for reassessment.
Study NCT01312792 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Injectable ampicillin followed by urgent referral
Description: Existing IMCI guideline denotes all severe pneumonia cases will be referred to the 1st level referral facilities after giving first dose of injectable antibiotics
Study NCT04879446 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Concentrated growth factor(CGF)
Description: Concentrated growth factor(CGF) liquid applied to the implant cavity and implant surface.
Study NCT04879446 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advanced platelet rich fibrin (A-PRF)
Description: Advanced platelet rich fibrin (A-PRF) liquid applied to the implant cavity and implant surface.
Study NCT04879446 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control side of concentrated growth factor study group
Description: Traditional implant methods applied.
Study NCT04879446 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control side of advanced platelet rich fibrin study group
Description: Traditional implant methods applied.
Study NCT02617121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: oral gabapentin 300 mg 1 hour before induction of anesthesia
Study NCT02617121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramosetron
Description: ramosetron 0.3 mg iv at end of surgery
Study NCT02617121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin and Ramosetron
Description: oral gabapentin 300 mg 1 hour before induction of anesthesia and ramosetron 0.3 mg iv at end of surgery
Study NCT01175239 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre
Description: Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre
Study NCT00839098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instruction Group: Power seat function usage instruction- verbal and written instruction
Description: Subjects assigned to the Intervention Group will be assigned to an Intervention Group Clinician. The Intervention Group Clinicians will provide the same training as the Control Group Clinicians, with the addition of discussing the Veteran's activity and seating function usage data, reviewing and providing a study pamphlet and compact disk as a reference guide on use of power seat functions.
Study NCT00178620 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary Percutaneous Coronary Intervention (PCI)
Study NCT02933463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embrace Wetbond
Description: not require an additional bonding agent hydrophilic, fluoride releasing
Study NCT02933463 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinpro sealant
Study NCT02832765 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: A
Description: Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions of the involved spinal bone metastases
Study NCT02832765 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: B
Description: Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions with an SIB with 40 Gy in 10 fractions to the metastasis of the involved spinal bone metastases
Study NCT02832765 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: C
Description: Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions of the involved spinal bone metastases
Study NCT02832765 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: D
Description: Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions with an SIB with 30 Gy in 5 fractions to the metastasis of the involved spinal bone metastases
Study NCT04485013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTX-080
Description: Variable dose (Q3W)
Study NCT04485013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTX-080
Description: Specified dose (Q3W)
Study NCT04485013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Specified dose (Q3W)
Study NCT04485013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Specified dose on specified days
Study NCT04485013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Specified dose (Q2W)
Study NCT04485013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Specified dose (Q2W)
Study NCT04635982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotape of the physical performance
Description: It has done a countermovement vertical jump, a twenty meter sprint and a kinesio tape application technique